Tuberculosis, unfortunately, remains alive and well and continues to be a cause for concern. It raises a wide range of questions at the moment -for example, are the current arrangements for chest clinics and public health practices adequate for satisfactory disease control and how tight should these controls be? Who should treat tuberculosis and who should purchase that treatment? Is HIV-related tuberculosis a real threat in the UK and should we be concerned about the emergence of multidrug-resistant disease? Should patients who have or might have multidrugresistant disease be compelled to accept treatment and isolation? What is the situation regarding BCG and appropriate screening of immigrants and refugees? None of these questions has a complete or satisfactory answer at the present time, so in this review we will address some of these issues in the light of current information.
The Joint Tuberculosis Committee of the British Thoracic Society will publish their updated code of practice for the control and prevention of tuberculosis in the next issue of Thorax. This document will define current practice on many of these issues on the basis of available information.
The rise in tuberculosis notifications in England and
Wales over the last few years'2 has reopened debate on the effectiveness and adequacy of current control measures. Despite this recent modest rise in notifications against a trend of decline over the last 40 years, the UK remains a low prevalence country for tuberculosis, although there is a substantial geographical variation3 with a number ofinner city areas and towns having a prevalence several times the national average. In low prevalence countries such as the UK, case finding and effective chemotherapy remain the corner stone of tuberculosis control, whereas preventive measures (BCG) are of some benefit also. These control measures will now be discussed in the light of the situation within the UK at the moment.
Prevention BCG VACCINATION
Routine unselected BCG vaccination oftuberculin negative school children was started in the 1950s and is still recommended for the [10] [11] [12] [13] [14] Compliance by doctors with standard treatment regimens has long been recognised as important to outcome24 by the selection of the appropriate drugs at the correct dosage given for the appropriate length oftime. This should now become the subject of standard national audit. Patient compliance is vital to successful outcome25 and should be monitored monthly at least. The role of the tuberculosis nurse or health visitor in monitoring the treatment process is vital and should be in close liaison with the local chest clinic and supervising respiratory physician. The main cause of disease relapse is poor compliance, so regular assessment of compliance should include prescription checks, pill counts, and urine tests for rifampicin. If combination tablets containing rifampicin are being used then this is a marker for all the drugs. In national surveys about 10% of all tuberculosis patients are poorly compliant. 26 Those with proven non-compliance or those thought likely to be non-compliant must have treatment switched to full supervision.'0 Standard treatment consists of rifampicin, isoniazid, and pyrazinamide for the first two months, followed by rifampicin and isoniazid for a further four months for respiratory and all non-respiratory tuberculosis (except for CNS tuberculosis where treatment should continue for 12 months altogether).'2 Ethambutol can be added to the initial treatment if local data suggest that there is a significant chance of isoniazid resistance in the patients' population group'2 or there is a history of previous treatment in a developing country. It is now recognised that an important reason for the increase in tuberculosis in the USA, apart from HIV, has been reduced funding in the 1970s and 1980s for tuberculosis control. This lesson should be heeded by health care planners in the UK.6869 Good systems are in place for tuberculosis control in the UK, but they must be maintained in the new era of the NHS internal market. The gloomy lessons from the USA suggest that it must be made explicit to purchasers that the key to prevention of multidrug-resistant tuberculosis is good public health and chest clinic control measures combined with careful compliance to appropriate multiple drug regimens. Directly observed treatment is now recommended in the USA707' and this, of course, is similar to the supervised approach which has been in the UK for many years. The ATS now recognises the wisdom of combination tablet therapy to prevent inadvertent or intentional monotherapy. 68 The Centers for Disease Control (CDC)22 have provided guidance on the management of contacts exposed to multidrug-resistant tuberculosis. They suggest that, if in vitro sensitivity testing shows less than 100% isoniazid or rifampicin resistance, these drugs should still be included in the regimen on account oftheir overall bactericidal potency. The efficacy ofalternative combination therapy for resistant disease remains undetermined by large controlled clinical studies. Suggested regimens include pyrazinamide with ethambutol or pyrazinamide with a fluoroquinolone (ciprofloxacin or ofloxacin). Appropriate duration of treatment also remains undetermined. The CDC suggests 6-12 months, but the safety of long term fluoroquinolones is uncertain. The lack of evidence for efficacy of these regimens raises problems for the contacts of cases infected with multidrug-resistant organisms. Generally such contacts should be followed for two years. If exposure is not regarded as high it is probably acceptable for HIV seronegative contacts to be followed up closely for two years rather than to be offered complex unproven potentially toxic drug combinations.
Organisation of services
Further problems that the emergence of drug-resistant tuberculosis in the USA has raised are the ethical issues relating to the rights of society generally versus the rights of individuals with drug resistant tuberculosis when it comes to difficulties with compliance with treatment, unwillingness to be treated and the degree to which coercion is acceptable.73
The situation in the UK Many of the procedures currently recommended in the USA have been in place in the UK for at least 60 years. Combination drug therapy with a single tablet is now routine and tuberculosis control measures are generally satisfactory. Multidrug-resistant disease is not yet a problem in the UK and the incidence ofprimary drug resistance remains low. 74 However, complacency would be misplaced, particularly in view of recent data showing that up to 27% of cases of tuberculosis may not be notified. ' In the UK, when drug-resistant tuberculosis does arise, treatment should only be carried out by a respiratory physician with experience of such cases. If isoniazid resistance is proven prior to treatment, a regimen of rifampicin, streptomycin, pyrazinamide, and ethambutol for two months, followed by rifampicin and ethambutol for a further seven months, has been shown to be effective. 77 If isoniazid resistance is detected after treatment has started, medication should be changed to rifampicin and ethambutol for 12 months with additional pyrazinamide for the first two months. 78 Drug resistance to rifampicin and isoniazid in the UK is uncommon at the moment, and the level is not increasing. 75 The general principle of management is that at least three drugs to which the organisms are sensitive are continued until cultures become negative, and then a minimum of two drugs are continued for a further nine months. Such treatment needs to be planned on an individual basis, and to be closely monitored to prevent the emergence offurther resistance.'2 Most cases of combined isoniazid/rifampicin resistance had received prior treatment outside the UK. 75 In the light of this information it may be wise to ensure that the initial treatment of reactivated tuberculosis previously treated abroad includes three drugs not previously given to the patient, as well as standard therapy, until the results of sensitivity tests are available.
Conclusion
This review has attempted to draw attention to some of the key issues surrounding tuberculosis today in the UK. Changes in disease prevalence, either generally or amongst special groups, the impact or otherwise of HIV, and the spectre of multidrug-resistant disease will determine our response in terms of BCG and treatment policy, but these trends will also stimulate a wider debate. If multidrugresistant disease becomes a problem, should patients who might be infectious be constrained to accept treatment within the new NHS? How should tuberculosis services be provided and purchased and who should manage both the patients and the programme and so be held accountable? The Joint Tuberculosis Committee of the British Thoracic Society actively monitors all aspects of tuberculosis in the UK including epidemiological and drug resistance trends in conjunction with its formal links with the Department of Health, Communicable Disease Surveillance Centre, and Public Health Laboratory Service. It will continue to produce amended recommendations as circumstances change. Finally, to safeguard against the hazards that tuberculosis could bring, we believe that tuberculosis must remain firmly within the domain of the respiratory physician and that rigorous adherence to national guidelines should remain in place until some of the questions raised in this review are answered. 
